Global Oligodendroglioma Treatment Market Professional Survey Report 2019

Table of Contents

Executive Summary

1 Industry Overview of Oligodendroglioma Treatment

• 1.1 Definition of Oligodendroglioma Treatment
• 1.2 Oligodendroglioma Treatment Segment by Type
  • 1.2.1 Global Oligodendroglioma Treatment Production Growth Rate Comparison by Types (2014-2025)
  • 1.2.2 Alisertib
  • 1.2.3 Bevacizumab
  • 1.2.4 CDX-1401
  • 1.2.5 Dasatinib
  • 1.2.6 DCVax-L
  • 1.2.7 IMA-950
  • 1.2.8 Others
• 1.3 Oligodendroglioma Treatment Segment by Applications
  • 1.3.1 Global Oligodendroglioma Treatment Consumption Comparison by Applications (2014-2025)
  • 1.3.2 Clinic
  • 1.3.3 Hospital
  • 1.3.4 ASCs
• 1.4 Global Oligodendroglioma Treatment Overall Market
  • 1.4.1 Global Oligodendroglioma Treatment Revenue (2014-2025)
  • 1.4.2 Global Oligodendroglioma Treatment Production (2014-2025)
  • 1.4.3 North America Oligodendroglioma Treatment Status and Prospect (2014-2025)
  • 1.4.4 Europe Oligodendroglioma Treatment Status and Prospect (2014-2025)
  • 1.4.5 China Oligodendroglioma Treatment Status and Prospect (2014-2025)
  • 1.4.6 Japan Oligodendroglioma Treatment Status and Prospect (2014-2025)
  • 1.4.7 Southeast Asia Oligodendroglioma Treatment Status and Prospect (2014-2025)
  • 1.4.8 India Oligodendroglioma Treatment Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis

• 2.1 Raw Material and Suppliers
• 2.2 Manufacturing Cost Structure Analysis of Oligodendroglioma Treatment
• 2.3 Manufacturing Process Analysis of Oligodendroglioma Treatment
• 2.4 Industry Chain Structure of Oligodendroglioma Treatment

3 Development and Manufacturing Plants Analysis of Oligodendroglioma Treatment

• 3.1 Capacity and Commercial Production Date
• 3.2 Global Oligodendroglioma Treatment Manufacturing Plants Distribution
• 3.3 Major Manufacturers Technology Source and Market Position of Oligodendroglioma Treatment
• 3.4 Recent Development and Expansion Plans

4 Key Figures of Major Manufacturers

• 4.1 Oligodendroglioma Treatment Production and Capacity Analysis
• 4.2 Oligodendroglioma Treatment Revenue Analysis
• 4.3 Oligodendroglioma Treatment Price Analysis
• 4.4 Market Concentration Degree

5 Oligodendroglioma Treatment Regional Market Analysis

• 5.1 Oligodendroglioma Treatment Production by Regions
  • 5.1.1 Global Oligodendroglioma Treatment Production by Regions
  • 5.1.2 Global Oligodendroglioma Treatment Revenue by Regions
• 5.2 Oligodendroglioma Treatment Consumption by Regions
• 5.3 North America Oligodendroglioma Treatment Market Analysis
  • 5.3.1 North America Oligodendroglioma Treatment Production
  • 5.3.2 North America Oligodendroglioma Treatment Revenue
  • 5.3.3 Key Manufacturers in North America
  • 5.3.4 North America Oligodendroglioma Treatment Import and Export
• 5.4 Europe Oligodendroglioma Treatment Market Analysis
  • 5.4.1 Europe Oligodendroglioma Treatment Production
  • 5.4.2 Europe Oligodendroglioma Treatment Revenue
  • 5.4.3 Key Manufacturers in Europe
  • 5.4.4 Europe Oligodendroglioma Treatment Import and Export
• 5.5 China Oligodendroglioma Treatment Market Analysis
  • 5.5.1 China Oligodendroglioma Treatment Production
  • 5.5.2 China Oligodendroglioma Treatment Revenue
  • 5.5.3 Key Manufacturers in China
  • 5.5.4 China Oligodendroglioma Treatment Import and Export
• 5.6 Japan Oligodendroglioma Treatment Market Analysis
  • 5.6.1 Japan Oligodendroglioma Treatment Production
  • 5.6.2 Japan Oligodendroglioma Treatment Revenue
  • 5.6.3 Key Manufacturers in Japan
  • 5.6.4 Japan Oligodendroglioma Treatment Import and Export
• 5.7 Southeast Asia Oligodendroglioma Treatment Market Analysis
  • 5.7.1 Southeast Asia Oligodendroglioma Treatment Production
  • 5.7.2 Southeast Asia Oligodendroglioma Treatment Revenue
  • 5.7.3 Key Manufacturers in Southeast Asia
  • 5.7.4 Southeast Asia Oligodendroglioma Treatment Import and Export
• 5.8 India Oligodendroglioma Treatment Market Analysis
  • 5.8.1 India Oligodendroglioma Treatment Production
  • 5.8.2 India Oligodendroglioma Treatment Revenue
  • 5.8.3 Key Manufacturers in India
  • 5.8.4 India Oligodendroglioma Treatment Import and Export

6 Oligodendroglioma Treatment Segment Market Analysis (by Type)

• 6.1 Global Oligodendroglioma Treatment Production by Type
• 6.2 Global Oligodendroglioma Treatment Revenue by Type
• 6.3 Oligodendroglioma Treatment Price by Type

7 Oligodendroglioma Treatment Segment Market Analysis (by Application)

• 7.1 Global Oligodendroglioma Treatment Consumption by Application
• 7.2 Global Oligodendroglioma Treatment Consumption Market Share by Application (2014-2019)

8 Oligodendroglioma Treatment Major Manufacturers Analysis

• 8.1 AngioChem Inc
  • 8.1.1 AngioChem Inc Oligodendroglioma Treatment Production Sites and Area Served
  • 8.1.2 AngioChem Inc Product Introduction, Application and Specification
  • 8.1.3 AngioChem Inc Oligodendroglioma Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.1.4 Main Business and Markets Served
• 8.2 Boehringer Ingelheim GmbH
  • 8.2.1 Boehringer Ingelheim GmbH Oligodendroglioma Treatment Production Sites and Area Served
  • 8.2.2 Boehringer Ingelheim GmbH Product Introduction, Application and Specification
  • 8.2.3 Boehringer Ingelheim GmbH Oligodendroglioma Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.2.4 Main Business and Markets Served
• 8.3 Bristol-Myers Squibb Co
  • 8.3.1 Bristol-Myers Squibb Co Oligodendroglioma Treatment Production Sites and Area Served
  • 8.3.2 Bristol-Myers Squibb Co Product Introduction, Application and Specification
  • 8.3.3 Bristol-Myers Squibb Co Oligodendroglioma Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.3.4 Main Business and Markets Served
• 8.4 Cavion LLC
  • 8.4.1 Cavion LLC Oligodendroglioma Treatment Production Sites and Area Served
  • 8.4.2 Cavion LLC Product Introduction, Application and Specification
  • 8.4.3 Cavion LLC Oligodendroglioma Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.4.4 Main Business and Markets Served
• 8.5 Celldex Therapeutics Inc
  • 8.5.1 Celldex Therapeutics Inc Oligodendroglioma Treatment Production Sites and Area Served
  • 8.5.2 Celldex Therapeutics Inc Product Introduction, Application and Specification
  • 8.5.3 Celldex Therapeutics Inc Oligodendroglioma Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.5.4 Main Business and Markets Served
• 8.6 Eli Lilly and Co
  • 8.6.1 Eli Lilly and Co Oligodendroglioma Treatment Production Sites and Area Served
  • 8.6.2 Eli Lilly and Co Product Introduction, Application and Specification
  • 8.6.3 Eli Lilly and Co Oligodendroglioma Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.6.4 Main Business and Markets Served
• 8.7 F. Hoffmann-La Roche Ltd
  • 8.7.1 F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Production Sites and Area Served
  • 8.7.2 F. Hoffmann-La Roche Ltd Product Introduction, Application and Specification
  • 8.7.3 F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.7.4 Main Business and Markets Served
• 8.8 Immatics Biotechnologies GmbH
  • 8.8.1 Immatics Biotechnologies GmbH Oligodendroglioma Treatment Production Sites and Area Served
  • 8.8.2 Immatics Biotechnologies GmbH Product Introduction, Application and Specification
  • 8.8.3 Immatics Biotechnologies GmbH Oligodendroglioma Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.8.4 Main Business and Markets Served
• 8.9 Ipsen SA
  • 8.9.1 Ipsen SA Oligodendroglioma Treatment Production Sites and Area Served
  • 8.9.2 Ipsen SA Product Introduction, Application and Specification
  • 8.9.3 Ipsen SA Oligodendroglioma Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.9.4 Main Business and Markets Served
• 8.10 Leadiant Biosciences Inc
  • 8.10.1 Leadiant Biosciences Inc Oligodendroglioma Treatment Production Sites and Area Served
  • 8.10.2 Leadiant Biosciences Inc Product Introduction, Application and Specification
  • 8.10.3 Leadiant Biosciences Inc Oligodendroglioma Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.10.4 Main Business and Markets Served
• 8.11 Millennium Pharmaceuticals Inc
• 8.12 Northwest Biotherapeutics Inc
• 8.13 Novartis AG
• 8.14 Pfizer Inc
• 8.15 Tocagen Inc

9 Development Trend of Analysis of Oligodendroglioma Treatment Market

• 9.1 Global Oligodendroglioma Treatment Market Trend Analysis
  • 9.1.1 Global Oligodendroglioma Treatment Market Size (Volume and Value) Forecast 2019-2025
• 9.2 Oligodendroglioma Treatment Regional Market Trend
  • 9.2.1 North America Oligodendroglioma Treatment Forecast 2019-2025
  • 9.2.2 Europe Oligodendroglioma Treatment Forecast 2019-2025
  • 9.2.3 China Oligodendroglioma Treatment Forecast 2019-2025
  • 9.2.4 Japan Oligodendroglioma Treatment Forecast 2019-2025
  • 9.2.5 Southeast Asia Oligodendroglioma Treatment Forecast 2019-2025
  • 9.2.6 India Oligodendroglioma Treatment Forecast 2019-2025
• 9.3 Oligodendroglioma Treatment Market Trend (Product Type)
• 9.4 Oligodendroglioma Treatment Market Trend (Application)
• 10.1 Marketing Channel
  • 10.1.1 Direct Marketing
  • 10.1.2 Indirect Marketing
• 10.3 Oligodendroglioma Treatment Customers

11 Market Dynamics

• 11.1 Market Trends
• 11.2 Opportunities
• 11.3 Market Drivers
• 11.4 Challenges
• 11.5 Influence Factors

12 Conclusion

13 Appendix

• 13.1 Methodology/Research Approach
  • 13.1.1 Research Programs/Design
  • 13.1.2 Market Size Estimation
  • 13.1.3 Market Breakdown and Data Triangulation
• 13.2 Data Source
  • 13.2.1 Secondary Sources
  • 13.2.2 Primary Sources
• 13.3 Author List